8-K: agilon health Reports Q1 2026 Results, Raises Guidance

agilon health announced strong first-quarter 2026 financial results, exceeding expectations and leading to an upward revision of full-year guidance for total revenues, medical margin, and Adjusted EBITDA.

Summary

• agilon health reported first-quarter 2026 results with total revenues of $1.42 billion, a decrease of 7% year-over-year, attributed to lower membership offset by improved pricing and contract economics.
• Gross profit increased to $65 million from $51 million in Q1 2025, and net income surged to $49 million from $12 million.
• Medical margin improved to $149 million, up 16% year-over-year, with a cost trend for Medicare Advantage members reserved at 7.4%.
• Adjusted EBITDA more than doubled to $54 million from $21 million in Q1 2025, boosted by strong ACO REACH performance.
• Total members on the platform decreased to 536,000, reflecting market and payor exits focused on profitability.
• The company raised its full-year 2026 guidance for total revenues to $5.68-$5.805 billion, medical margin to $350-$400 million, and Adjusted EBITDA to $10-$40 million.
• agilon health's balance sheet as of March 31, 2026, showed $303 million in cash, cash equivalents, and marketable securities, with total debt of $32 million.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive report due to strong performance in key profitability metrics and an upward revision of future guidance, despite a decrease in total membership.

Positives

• Significant increase in net income to $49 million in Q1 2026 from $12 million in Q1 2025.
• Medical margin grew by 16% year-over-year to $149 million.
• Adjusted EBITDA more than doubled, increasing by 162% to $54 million in Q1 2026.
• Full-year 2026 guidance for total revenues, medical margin, and Adjusted EBITDA has been raised.
• Improved pricing and contract economics are offsetting lower membership numbers.
• Strong performance from ACO REACH initiatives contributed to higher Adjusted EBITDA.
• Disciplined approach to contracting focused on profitability is yielding positive results.
• Cash, cash equivalents, and marketable securities stand at $303 million, with low total debt of $32 million.

Negatives

• Total members on the platform decreased by 11% year-over-year to 536,000 as of March 31, 2026.
• Total revenue decreased by 7% year-over-year to $1.42 billion in Q1 2026.
• Membership decline is due to previously disclosed market exits and payor exits.

Risks

• Medical expenses incurred on behalf of members may exceed revenues received.
• Failure to identify and develop successful new geographies, physician partners, and payors.
• Inaccuracy in estimates of members' risk adjustment factors, medical services expense, and incurred but not reported claims.
• Public health crises, such as pandemics or epidemics, could adversely affect the company.
• Security breaches, cybersecurity attacks, loss of data, and other disruptions to information systems.
• Reliance on a limited number of key payors and the limited terms of contracts.
• Changes to federal government healthcare programs and dependence on them.
• Uncertain or adverse economic and macroeconomic conditions, including a decrease in government expenditures.

Future Outlook

Full-year 2026 guidance has been raised for total revenues ($5.68-$5.805 billion), medical margin ($350-$400 million), and Adjusted EBITDA ($10-$40 million). Guidance for the second quarter of 2026 includes total revenues of $1.435-$1.475 billion, medical margin of $115-$130 million, and Adjusted EBITDA of $15-$25 million.

Management Comments

• "Our strong first-quarter performance and increase in full-year 2026 guidance reflects disciplined execution and progress against our strategic priorities."
• "We are seeing early returns from investments in data and technology, clinical execution, and operating discipline."
• "We are also strengthening our Total Care Model—expanding clinical pathways, improving quality, and deepening payor alignment—positioning us for more predictable outcomes and sustained margin expansion."
• "We remain confident in our 2026 outlook and long-term growth trajectory."
• "We are also excited to welcome Tim ORourke as CEO, who brings more than 25 years of healthcare leadership. Under Tim's leadership we expect to further sharpen our focus on execution with faster pull through from action to outcome and deliver increased value for all stakeholders."

Industry Context

StockSavvy.ai notes that agilon health's results and raised guidance align with a broader industry trend towards value-based care models, where providers are incentivized for quality outcomes rather than volume of services. The company's focus on physician partnerships and technology enablement is a key strategy in this evolving healthcare landscape.

Comparison to Industry Standards

• While specific comparable company data is not provided in the filing, agilon health's reported Adjusted EBITDA growth of 162% significantly outpaces typical growth rates for many established healthcare service providers.
• The company's medical margin improvement of 16% is a strong indicator of effective cost management within value-based contracts, a critical benchmark for success in the sector.
• The strategic shift towards profitability through disciplined contracting, as evidenced by member count adjustments, reflects a common challenge and objective for companies navigating the transition to value-based care, aiming for sustainable growth over rapid expansion.

Management Changes

Stakeholder Impact

• Shareholders: Positively impacted by improved financial performance and raised guidance, potentially leading to increased stock value.
• Physicians: Benefit from strengthened partnerships and the Total Care Model, aiming for more predictable outcomes and sustained margin expansion.
• Payors: Experience deeper alignment and improved quality metrics, contributing to more predictable outcomes.
• Employees: Potential for increased value and focus under new leadership, with continued investment in technology and clinical execution.

Next Steps

• Host a conference call on May 6, 2026, at 4:30 PM Eastern Time to discuss Q1 2026 results.
• Continue to execute on strategic priorities including investments in data and technology, clinical execution, and operating discipline.
• Strengthen the Total Care Model by expanding clinical pathways, improving quality, and deepening payor alignment.
• Focus on execution under new CEO Tim O'Rourke to drive faster pull-through from action to outcome.

Key Dates

Recommendation

While the company demonstrated strong operational improvements and raised guidance, the continued decline in total membership and the inherent complexities of the healthcare industry warrant a cautious 'hold' rating. The successful integration of new leadership and sustained execution on profitability initiatives will be key factors for future upside.

Keywords

agilon health, 8-K, Q1 2026 Results, Financial Guidance, Medical Margin, Adjusted EBITDA, Medicare Advantage, Value-Based Care